Bacillus amyloliquefaciens superoxide dismutase

Bacillus amyloliquefaciens superoxide dismutase (also known as GF103 or SOD-BA) is a recombinant, mutant manganese-containing superoxide dismutase (Mn-SOD) enzyme originally derived from the bacterium *Bacillus amyloliquefaciens* (specifically strain GF423, also classified as *Bacillus velezensis*). Developed by HLB Genex (formerly GenoFocus) and its subsidiary BiomLogic, along with partner Baobab AiBIO, this enzyme acts as a potent antioxidant by catalyzing the dismutation of superoxide radicals into oxygen and hydrogen peroxide, thereby mitigating oxidative stress and downstream inflammatory pathways. It is formulated as an orally administered, enteric-coated therapeutic (often coated with shellac to resist gastric acid) to target oxidative stress-related conditions. The drug is in clinical development for wet age-related macular degeneration (wet AMD), diabetic macular edema, and mucositis, and is being investigated preclinically for dry eye disease, inflammatory bowel disease (colitis), and acute kidney injury.

Brand names

SODyZYM

Other names

Bacillus velezensis superoxide dismutaseBacillus-derived manganese superoxide dismutaseBacillus-derived superoxide dismutaseMn-SODmanganese superoxide dismutase